ADVERTISEMENT

Israel

Country

New Measures Can Cut Israel’s Drug Approval Time To Just 70 Days

Israel has introduced a new framework to expedite the marketing approval of medicines, make the country a more attractive destination for drug registration and help reduce drug prices through market competition.

Teva Shares Encouraging Patient Survey Data For Long-Acting Olanzapine

Doubling down on previously shared data from the firm’s STELARIS trial, Teva has reported further findings from a survey featuring subjects and professionals involved in the Phase III study for its proposed long-acting olanzapine injectable.

US Nutrition Market News: Anheuser-Busch, TopGum, SameDaySupplements, Resbiotic, More

Anheuser-Busch enters energy drinks space with 1st Phorm; TopGum adds Canadian gummy manufacturer; Resbiotic Nutrition expands distribution to Mexico; SameDaySupplements adds custom Stacks; ‘tailored offerings’ for supplement payment processing; marketing boost for Enroute Nutrition for dietary management of surgery.

Israel Startup Licenses Stanford Institute Metabolites To Develop Weight Loss Supplements

Israeli startup by biomedical researcher and entrepreneur Morris Laster using research from ChEM-H Institute scholar at Stanford to will develop and market compounds as nutraceuticals to offer an effective, affordable and side-effect-free solution for weight loss.

Teva Agrees $750m Deal To Draw A Line Under Israeli Tax Tussle

Teva enjoyed a favorable tax status for years in its domestic Israel. However, after the firm battled in court against challenges to its historic tax payments, Teva has now agreed a three-quarters-of-a-billion dollar settlement agreement with the Israel Tax Authority.

Final Funding Blow For J&J’s Spravato In England, Despite Reimbursement In 26 Other Countries

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

Viatris And Mapi Knocked Back On Once-Monthly US Copaxone Rival

Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.

Unipharm Plavix Ruling May Change Game On Recouping Lost Generics Profits In Israel

In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.

A Year Of Change: Looking Back At Francis’ First Year At Teva

As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.

Israeli Biopharma Leaders Focus On Near-Term Targets

Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.